Analyst Research

Report Title Price
Provider: Pechala's Reports
$15.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Depomed Inc Announces Serada NDA Acceptance And FDA Advisory Committee Meeting


Monday, 15 Oct 2012 08:00am EDT 

Depomed Inc announced that New Drug Application (NDA) for Serada has been accepted for filing by the U.S. Food and Drug Administration (FDA). Depomed submitted the Serada NDA to FDA on July 31, 2012. Depomed is seeking approval to market and sell Serada in the United States for the treatment of menopausal hot flashes. Serada is an investigational product and is not approved to treat any disease or condition. 

Company Quote

12.96
-0.44 -3.28%
11 Jul 2014